Waist to Height Ratio: What Your Numbers Mean

Your waist to height ratio is your waist measurement divided by your height, using the same units for both. It gives a quick estimate of central adiposity, which means fat stored around the abdomen. Doctors read this number alongside body mass index (BMI) rather than using it to diagnose conditions.

UK guidance from NICE, updated in January 2026, sets the main boundary at 0.5 for adults with a BMI under 35. A ratio from 0.4 to 0.49 reflects healthy central fat. A result of 0.5 or higher signals added health risk, which a clinician reads alongside other measures.

How to calculate waist to height ratio and read the ranges

You calculate the ratio by dividing waist size by height in inches or centimeters. In NICE's example, a 38-inch waist divided by a 67-inch height equals 0.57. A 90-centimeter waist is 0.50 at 180 centimeters tall, but 0.60 at 150 centimeters tall.

NICE's 2022 adult recommendations cover men and women of all ethnicities with a BMI under 35 kg/m², including muscular adults. The categories below track rising risk for type 2 diabetes, hypertension, and cardiovascular disease.

Waist circumference on a GLP-1: tirzepatide trial numbers

BMI compares total weight against height, so it cannot show where body fat sits. Two people in the same BMI bracket can have very different waist sizes and health risks.

In the 2022 SURMOUNT-1 trial in the New England Journal of Medicine, researchers studied 2,539 adults without diabetes over 72 weeks. Mean waist circumference fell by 14.0 cm on 5 mg, 17.7 cm on 10 mg, and 18.5 cm on 15 mg.

Placebo participants averaged a 4.0 cm reduction over the same period. In inches, those trial averages equal roughly 5.5, 7.0, and 7.3 inches, versus 1.6 inches on placebo.

Branded Zepbound carries prescribing information revised in August 2026 for weight management and obstructive sleep apnea in qualifying adults. Tirzepatide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: this compounded formulation is not FDA-approved.

Healthy waist size for men and women vs waist to height ratio

In guidance updated in December 2025, the National Heart, Lung, and Blood Institute (NHLBI) uses waist circumference alone rather than a height ratio. Heart and diabetes risk rises at more than 35 inches for women or more than 40 inches for men.

A 2020 consensus statement in Nature Reviews Endocrinology explains how fixed waist cutoffs vary across populations. Customary white-adult cutoffs (>102 cm for men and >88 cm for women) originally matched BMI 30.0 kg/m². For Asian Indian adults, that paper lists lower thresholds of ≥90 cm for men and ≥80 cm for women.

Tape location also differs between guidelines. NICE measures midway between the lower ribs and top of the hips, while NHLBI describes a spot just above your hipbones. Because placement shifts the number, the 2020 consensus advises using one measurement protocol consistently.

A 2012 review in Obesity Reviews pooled 31 papers covering more than 300,000 adults. Waist to height ratio improved screening discrimination—how well a test separates risk groups—by 4% to 5% over BMI. That percentage reflects population screening accuracy, not a personal drop in disease risk.

As of October 17, 2026, the day this article was written, recent evidence includes a September 7, 2026 Korean study of 2,412 adults. Researchers used area under the curve (AUC), a 0-to-1 score of how well a test separates groups with metabolic risk factors.

In adults aged 40 to 64, the ratio scored 0.780, modestly beating BMI at 0.766 (p = .003). It performed statistically similarly to waist circumference alone, which scored 0.776 (Holm-adjusted p = .194).

Visceral fat vs waist size: what a tape cannot separate

A tape measure captures outer circumference, so it cannot separate subcutaneous fat under the skin from visceral fat around organs. A tape does not measure fat compartments or lean tissue separately; DEXA scan results explained describes a separate body-composition assessment.

A 2007 trial in the New England Journal of Medicine randomized 412 adults with HIV and abdominal fat accumulation (86% men) for 26 weeks. On CT scans between the L4 and L5 vertebrae, visceral fat changed by −15.2% with tesamorelin versus +5.0% with placebo.

Meanwhile, exterior waist size changed by −2.6 cm (about 1.0 inch) on tesamorelin versus −0.8 cm (about 0.3 inches) on placebo. Those figures belong to the studied HIV population rather than general weight loss; see tesamorelin for belly fat for context.

Branded Egrifta WR carries prescribing information revised 3/2025 for excess abdominal fat in adults with HIV and lipodystrophy. The label states that it is not indicated for weight loss management. Tesamorelin prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: this compounded formulation is not FDA-approved.

Semaglutide waist results and the clinical trial table

In the 2021 STEP 1 trial in the New England Journal of Medicine, 1,961 adults without diabetes were followed for 68 weeks. Once-weekly injected semaglutide 2.4 mg reduced waist circumference by 13.54 cm (about 5.3 inches), versus 4.13 cm (about 1.6 inches) on placebo.

The estimated difference between groups was −9.42 cm (95% CI, −10.30 to −8.53; P<0.001). For this STEP 1 comparison, the 95% confidence interval (CI) describes uncertainty around the estimated difference between groups; standard deviation (SD) in the table describes how much individual changes varied. The table below compares all three trials, and what 15% weight loss looks like covers STEP 1's broader results.

These studies did not compare the medicines directly. SURMOUNT-1's 5 mg waist comparison was not adjusted for the greater chance of false-positive findings when testing many outcomes. The published waist endpoints do not report individual waist-to-height-ratio changes or how many participants crossed 0.5.

Branded Wegovy carries prescribing information revised in June 2026, while FDA compounding guidance notes that compounded drugs are not FDA-approved. Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: this compounded formulation is not FDA-approved.

When the ratio does not apply and how a provider reads it

The NHS waist to height ratio calculator, reviewed in February 2025, warns that you should not use it to diagnose any conditions. It excludes pregnancy, diagnosed or suspected eating disorders, conditions affecting height, an adult BMI over 35, and children under 5.

Both the Zepbound and Wegovy labels warn of persistent or severe abdominal pain, sometimes radiating to the back. If pancreatitis is suspected, both labels direct discontinuing the medication and starting appropriate management. In STEP 1 and SURMOUNT-1, gastrointestinal events like nausea and diarrhea were typically mild to moderate in most participants.

Egrifta WR is contraindicated in pregnancy, active malignancy, pituitary axis disruption, and known hypersensitivity. Its label also calls for evaluating blood glucose before and during therapy and monitoring IGF-1 (a hormone lab marker). Long-term cardiovascular safety has not been established for Egrifta WR, and clinical trials did not test compounded formulations.

A clinician reads your waist measurement alongside labs and medical history rather than giving you a single number to aim for. Although compounded formulations are not FDA-approved, a licensed provider may still prescribe — that decision is between you and your doctor. At Promise, a licensed provider reviews every request and not everyone qualifies.